Results 141 to 150 of about 1,187,088 (318)

Epilepsy‐Associated Variants of a Single SCN1A Codon Exhibit Divergent Functional Properties

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Pathogenic variants in SCN1A, which encodes the voltage‐gated sodium channel NaV1.1, are associated with multiple epilepsy syndromes exhibiting a range of clinical severity. SCN1A variants are reported in different syndromes, including Dravet syndrome, which is associated with loss‐of‐function, whereas neonatal/infantile‐onset ...
Lanie N. Liebovitz   +3 more
wiley   +1 more source

GAD65 Antibody ELISA With Extended Reportable Range: Validation and Guidance for Neurological Practice

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To (1) validate GAD65‐ELISA detection and quantification for type 1 diabetes mellitus and autoimmune neurological diagnoses, (2) correlate ELISA results (reference range < 5 IU/mL) with established radioimmunoprecipitation assay (RIA; ≤ 0.02 nmol/L), and (3) define ELISA clinical utility and pitfalls.
Andrew McKeon   +11 more
wiley   +1 more source

Molecular characterisation of recombinant human pyroglutamyl peptidase (type I) [PDF]

open access: yes, 2005
Pyroglutamyl Peptidase I (PAP1, EC 3.4.19.3) hydrolytically cleaves pyroglutamic acid (pGlu) from the N-terminal of most pGlu-peptides. In higher organisms Thyrothropin Releasing Hormone is a notable biologically active substrate of PAP1. The sequence of
Vaas, Paul-Roman
core  

Plasma EV Proteomics Identifies ECM Remodeling and Inflammatory Proteins LUM and C7 as Candidate Biomarkers in FSHD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy (FSHD) is one of the most debilitating and common muscular dystrophies. Despite its severity, no approved therapy exists for FSHD patients. However, several therapeutic candidates are currently under development, and some have recently entered clinical trials, marking the need for reliable ...
Mustafa Bilal Bayazit   +11 more
wiley   +1 more source

Characterizing Cutaneous α‐Synuclein Deposition and Seeding Activity in Parkinson's Disease Subtypes

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cutaneous phosphorylated α‐synuclein (p‐syn) and α‐synuclein seeding activity are promising biomarkers for Parkinson's disease (PD), but their clinical value remains uncertain due to disease heterogeneity. This study evaluates these two biomarkers in PD patients to inform phenotype‐specific diagnosis and disease severity assessment ...
Yuting Jin   +8 more
wiley   +1 more source

Introduction of recombinant antigens against Jembrana Disease Virus into plants [PDF]

open access: yes, 2010
Jembrana disease virus (JDV) is a bovine lentivirus that causes an acute severe disease syndrome in banteng cattle (Bos javanicus) in Indonesia. In order to develop a vaccine, JDV capsid (CA) protein together with transactivator of transcription (Tat ...
Singh, Meenu
core   +1 more source

Macrophage Immune Response Suppression by Recombinant Mycobacterium tuberculosis Antigens, the ESAT-6, CFP-10, and ESAT-6/CFP-10 Fusion Proteins

open access: yesIranian Journal of Medical Sciences, 2016
Background: Macrophage immune responses are affected by the secretory proteins of Mycobacterium tuberculosis (Mtb). This study aimed to examine the immune responses of macrophages to Mtb secretory antigens, namely ESAT-6, CFP-10, and ESAT-6/CFP-10 ...
Atefeh Seghatoleslam   +4 more
doaj  

Tuning Mechanoreceptor Signaling Enhances the Adjuvant Effect of Biomaterial Vaccines

open access: yesAdvanced Functional Materials, EarlyView.
Matrix stiffness serves as an independent immunological signal in biomaterial vaccines. Stiffer microporous hydrogel vaccines enhance dendritic cell maturation and migration to draining lymph nodes, promote T follicular helper cell expansion through Yap/Taz signaling, and increase antigen‐specific antibody production.
Lily Shang   +13 more
wiley   +1 more source

NOVEL PROCESSES AND PRODUCTS FOR RECOMBINANT PRODUCTION OF BIOPHARMACEUTICALS [PDF]

open access: yes, 2009
The monoclonal antibody market represents the fastest-growing segment within the biopharmaceutical industry (Evans and Das 2005). Indeed, recombinant antibodies and antibody fragments are widespread tools for research, diagnostics and therapy (Joosten et
Giuliani, Maria
core  

Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles

open access: yesAdvanced Healthcare Materials, EarlyView.
Engineered red blood cell‐derived extracellular vesicles (eRBCEVs) are synthesized via controlled microfluidic assembly from native RBC lipids, enabling tunable encapsulation of proteins, nucleic acids, nanoparticles, and viral vectors. The platform demonstrates reproducible nanoscale architecture, preserved membrane composition, and functional cargo ...
Chiranth K. Nagaraj   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy